In the last trading session, 1.5 million shares of the Vir Biotechnology Inc (NASDAQ:VIR) were traded, and its beta was 1.14. Most recently the company’s share price was $9.38, and it changed around -$0.46 or -4.67% from the last close, which brings the market valuation of the company to $1.29B. VIR currently trades at a discount to its 52-week high of $14.45, offering almost -54.05% off that amount. The share price’s 52-week low was $6.56, which indicates that the current value has risen by an impressive 30.06% since then. We note from Vir Biotechnology Inc’s average daily trading volume that its 10-day average is 1.39 million shares, with the 3-month average coming to 2.13 million.
Vir Biotechnology Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.56. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 2 recommended VIR as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Vir Biotechnology Inc is expected to report earnings per share of -0.87 for the current quarter.
Vir Biotechnology Inc (NASDAQ:VIR) trade information
Instantly VIR has showed a red trend with a performance of -4.67% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 10.67 on recent trading dayincreased the stock’s daily price by 12.09%. The company’s shares are currently up 27.79% year-to-date, but still down -6.01% over the last five days. On the other hand, Vir Biotechnology Inc (NASDAQ:VIR) is -24.84% down in the 30-day period. We can see from the shorts that 7.86 million shares have been sold at a short interest cover period of 2.19 day(s).
The consensus price target as assigned by Wall Street analysts is $20, which translates to bulls needing to increase their stock price by 53.1% from its current value. Analyst projections state that VIR is forecast to be at a low of $20 and a high of $20.
Vir Biotechnology Inc (VIR) estimates and forecasts
The year-over-year growth rate is expected to be -20.34%, down from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 8.14M in revenue for the current quarter. 4 analysts expect Vir Biotechnology Inc to make 13.66M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 16.79M and 56.38M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -51.51%. Forecasts for the next quarter put sales growth at -75.77%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -34.12%. Vir Biotechnology Inc earnings are expected to increase by 15.42% in 2025, but the outlook is positive 8.69% per year for the next five years.
VIR Dividends
Vir Biotechnology Inc’s next quarterly earnings report is expected to be released in March.
Vir Biotechnology Inc (NASDAQ:VIR)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 11.90% of Vir Biotechnology Inc shares, and 73.55% of them are in the hands of institutional investors. The stock currently has a share float of 83.49%. Vir Biotechnology Inc stock is held by 289.0 institutions, with SB INVESTMENT ADVISERS (UK) LTD being the largest institutional investor. By 2024-06-30, it held 12.3329% of the shares, which is about 16.68 million shares worth $148.49 million.
BLACKROCK INC., with 12.1482% or 16.43 million shares worth $146.26 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Nov 30, 2024 . The former held 5.9 shares worth $55.34 million, making up 4.28% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 3.46 shares worth around $32.47 million, which represents about 2.51% of the total shares outstanding.
